{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:03:43Z","timestamp":1787317423777,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-025-01987-w","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:15:10Z","timestamp":1760361310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT"],"prefix":"10.1186","volume":"17","author":[{"given":"Ya-Xue","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Ling","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Pei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Ning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Sheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"3","key":"1987_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1987_CR2","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.31311","volume":"124","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Labopin M, Socie G, et al. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer. 2018;124(10):2134\u201341.","journal-title":"Cancer"},{"issue":"4","key":"1987_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/joim.12720","volume":"283","author":"C Craddock","year":"2018","unstructured":"Craddock C, Versluis J, Labopin M, et al. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. J Intern Med. 2018;283(4):371\u20139.","journal-title":"J Intern Med"},{"issue":"10","key":"1987_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The european leukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1987_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3324\/haematol.2015.140996","volume":"101","author":"C Craddock","year":"2016","unstructured":"Craddock C, Labopin M, Robin M, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101(7):879\u201383.","journal-title":"Haematologica"},{"issue":"11","key":"1987_CR6","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","volume":"116","author":"O Goodyear","year":"2010","unstructured":"Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116(11):1908\u201318.","journal-title":"Blood"},{"issue":"1","key":"1987_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","volume":"115","author":"LI S\u00e1nchez-Abarca","year":"2010","unstructured":"S\u00e1nchez-Abarca LI, Gutierrez-Cosio S, Santamar\u00eda C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115(1):107\u201321.","journal-title":"Blood"},{"issue":"4","key":"1987_CR8","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8277","volume":"47","author":"Z Li","year":"2022","unstructured":"Li Z, Zhang J, Zhou M, et al. Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro. Oncol Rep. 2022;47(4):66.","journal-title":"Oncol Rep"},{"issue":"12","key":"1987_CR9","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.3390\/ijms21124281","volume":"21","author":"S Kim","year":"2020","unstructured":"Kim S, Santhanam S, Lim S, et al. Targeting Histone deacetylases to modulate graft-versus-host disease and graft-versus-leukemia. Int J Mol Sci. 2020;21(12):4281.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1987_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13016","volume":"167","author":"M Kirschbaum","year":"2014","unstructured":"Kirschbaum M, Gojo I, Goldberg SL, et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. 2014;167(2):185\u201393.","journal-title":"Br J Haematol"},{"issue":"1","key":"1987_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.68","volume":"4","author":"P Tan","year":"2014","unstructured":"Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4(1):e170.","journal-title":"Blood Cancer J"},{"issue":"7","key":"1987_CR12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"2","key":"1987_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","volume":"15","author":"XJ Huang","year":"2009","unstructured":"Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(2):257\u201365.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1987_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101596","volume":"72","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang P, Cassady K, et al. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2022;72:101596.","journal-title":"Transpl Immunol"},{"key":"1987_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/bs.ircmb.2024.06.003","volume":"387","author":"K Hayatigolkhatmi","year":"2024","unstructured":"Hayatigolkhatmi K, Valzelli R, El Menna O, et al. Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options. Int Rev Cell Mol Biol. 2024;387:27\u201375.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"24","key":"1987_CR16","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","volume":"66","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu QF, Lin R, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull (Beijing). 2021;66(24):2498\u2013505.","journal-title":"Sci Bull (Beijing)"},{"issue":"2","key":"1987_CR17","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11(2):e147\u201359.","journal-title":"Lancet Haematol"},{"issue":"6","key":"1987_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2016-03-674127","volume":"128","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Walter RB, Tallman MS, et al. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood. 2016;128(6):763\u201373.","journal-title":"Blood"},{"issue":"4","key":"1987_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1586\/ehm.10.32","volume":"3","author":"AJ Barrett","year":"2010","unstructured":"Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol. 2010;3(4):429\u201341.","journal-title":"Expert Rev Hematol"},{"issue":"21","key":"1987_CR20","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","volume":"4","author":"B Oran","year":"2020","unstructured":"Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580\u20138.","journal-title":"Blood Adv"},{"issue":"6","key":"1987_CR21","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41409-019-0677-z","volume":"55","author":"Y Ma","year":"2020","unstructured":"Ma Y, Qu C, Dai H, et al. Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia. Bone Marrow Transplant. 2020;55(6):1206\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"36","key":"1987_CR22","first-page":"4249","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML After HSCT: an open-label, multicenter. Randomized Controlled Trial J Clin Oncol. 2020;38(36):4249\u201359.","journal-title":"Randomized Controlled Trial J Clin Oncol"},{"issue":"6","key":"1987_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00277-022-04821-y","volume":"101","author":"KJ Wattebled","year":"2022","unstructured":"Wattebled KJ, Drumez E, Coiteux V, et al. Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2022;101(6):1321\u201331.","journal-title":"Ann Hematol"},{"issue":"12","key":"1987_CR24","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1080\/10428194.2020.1789630","volume":"61","author":"N Ali","year":"2020","unstructured":"Ali N, Tomlinson B, Metheny L, et al. Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leuk Lymphoma. 2020;61(12):2839\u201349.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"1987_CR25","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/febs.13142","volume":"282","author":"P Mehdipour","year":"2015","unstructured":"Mehdipour P, Santoro F, Minucci S. Epigenetic alterations in acute myeloid leukemias. FEBS J. 2015;282(9):1786\u2013800.","journal-title":"FEBS J"},{"issue":"1","key":"1987_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","volume":"59","author":"L Yang","year":"2024","unstructured":"Yang L, Lai X, Yang T, et al. Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Bone Marrow Transplant. 2024;59(1):85\u201392.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"1987_CR27","doi-asserted-by":"publisher","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","volume":"27","author":"T Guillaume","year":"2021","unstructured":"Guillaume T, Th\u00e9pot S, Peterlin P, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome. Transplant Cell Ther. 2021;27(10):839.e1-839.e6.","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"1987_CR28","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/bmt.2017.31","volume":"52","author":"J El-Cheikh","year":"2017","unstructured":"El-Cheikh J, Massoud R, Fares E, et al. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. Bone Marrow Transplant. 2017;52(6):918\u201321.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1987_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","volume":"58","author":"A Kent","year":"2023","unstructured":"Kent A, Schwartz M, McMahon C, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023;58(8):849\u201354.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"1987_CR30","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/cas.15048","volume":"112","author":"Y Wei","year":"2021","unstructured":"Wei Y, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021;112(9):3636\u201344.","journal-title":"Cancer Sci"},{"issue":"3","key":"1987_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/jha2.915","volume":"5","author":"K Parks","year":"2024","unstructured":"Parks K, Diebold K, Salzman D, et al. Low-dose decitabine plus venetoclax as post-transplant maintenance for high-risk myeloid malignancies. EJHaem. 2024;5(3):560\u20134.","journal-title":"EJHaem"},{"issue":"5","key":"1987_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/bmt.2015.234","volume":"51","author":"Z Jedlickova","year":"2016","unstructured":"Jedlickova Z, Schmid C, Koenecke C, et al. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(5):663\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1987_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","volume":"57","author":"C Schmid","year":"2022","unstructured":"Schmid C, Labopin M, Schaap N, et al. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplant. 2022;57(2):215\u201323.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"1987_CR34","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1007\/s00277-023-05406-z","volume":"102","author":"S Jiang","year":"2023","unstructured":"Jiang S, Lu X, Wei R, et al. Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study. Ann Hematol. 2023;102(11):3205\u201316.","journal-title":"Ann Hematol"},{"issue":"5","key":"1987_CR35","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/cancers15051609","volume":"15","author":"T Caballero-Vel\u00e1zquez","year":"2023","unstructured":"Caballero-Vel\u00e1zquez T, P\u00e9rez-L\u00f3pez O, Yeguas Bermejo A, et al. prognostic value of measurable residual disease in patients with AML undergoing HSCT: a multicenter study. Cancers (Basel). 2023;15(5):1609.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1987_CR36","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190\u20137.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1987_CR37","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993\u20133002.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1987_CR38","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","volume":"56","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56(5):1180\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"1987_CR39","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766\u201375.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1987_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12185-022-03352-6","volume":"116","author":"F Biavasco","year":"2022","unstructured":"Biavasco F, Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022;116(3):341\u201350.","journal-title":"Int J Hematol"},{"issue":"24","key":"1987_CR41","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","volume":"23","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Mr\u00f3zek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(24):5705\u201317.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1987_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bbmt.2007.10.006","volume":"14","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, Pasquini MC, P\u00e9rez WS, et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008;14(2):187\u201396.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1987_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1182\/bloodadvances.2019000168","volume":"4","author":"S Al-Harbi","year":"2020","unstructured":"Al-Harbi S, Aljurf M, Mohty M, et al. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 2020;4(1):229\u201338.","journal-title":"Blood Adv"},{"issue":"9","key":"1987_CR44","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-488114","volume":"123","author":"M Bots","year":"2014","unstructured":"Bots M, Verbrugge I, Martin BP, et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood. 2014;123(9):1341\u201352.","journal-title":"Blood"},{"issue":"2","key":"1987_CR45","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/sj.leu.2402776","volume":"17","author":"MI Klisovic","year":"2003","unstructured":"Klisovic MI, Maghraby EA, Parthun MR, et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1\/ETO-positive leukemic cells. Leukemia. 2003;17(2):350\u20138.","journal-title":"Leukemia"},{"issue":"12","key":"1987_CR46","first-page":"2766","volume":"59","author":"J Wang","year":"1999","unstructured":"Wang J, Saunthararajah Y, Redner RL, et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999;59(12):2766\u20139.","journal-title":"Cancer Res"},{"issue":"8","key":"1987_CR47","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s00277-024-05853-2","volume":"103","author":"W Guo","year":"2024","unstructured":"Guo W, Zhang H, Zheng Y, et al. Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT. Ann Hematol. 2024;103(8):3155\u201363.","journal-title":"Ann Hematol"},{"issue":"22","key":"1987_CR48","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"7","key":"1987_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.59","volume":"5","author":"HA Hou","year":"2015","unstructured":"Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5(7):e331.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1987_CR50","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"10","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;10(2):16010.","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"1987_CR51","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1002\/cncr.30203","volume":"122","author":"TM Kadia","year":"2016","unstructured":"Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484\u201391.","journal-title":"Cancer"},{"issue":"11","key":"1987_CR52","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG, Maiti A, Kadia TM, et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 2022;12(11):2516\u201329.","journal-title":"Cancer Discov"},{"issue":"14","key":"1987_CR53","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1080\/10428194.2022.2123228","volume":"63","author":"M Shahzad","year":"2022","unstructured":"Shahzad M, Tariq E, Chaudhary SG, et al. Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2022;63(14):3409\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1987_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11(1):33.","journal-title":"J Hematol Oncol"},{"issue":"438","key":"1987_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2018.08.030","volume":"1","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen H, Chen J, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett. 2018;1(438):63\u201375.","journal-title":"Cancer Lett"},{"issue":"8","key":"1987_CR56","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D'Souza","year":"2020","unstructured":"D\u2019Souza A, Fretham C, Lee SJ, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26(8):e177\u201382.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"1987_CR57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","volume":"22","author":"C Craddock","year":"2016","unstructured":"Craddock C, Jilani N, Siddique S, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2016;22(2):385\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1987_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","volume":"116","author":"J Choi","year":"2010","unstructured":"Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129\u201339.","journal-title":"Blood"},{"issue":"9","key":"1987_CR59","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/leu.2013.64","volume":"27","author":"T Schroeder","year":"2013","unstructured":"Schroeder T, Fr\u00f6bel J, Cadeddu RP, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27(9):1910\u20133.","journal-title":"Leukemia"},{"issue":"14","key":"1987_CR60","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","volume":"119","author":"OC Goodyear","year":"2012","unstructured":"Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361\u20139.","journal-title":"Blood"},{"issue":"11","key":"1987_CR61","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1073\/pnas.0400380101","volume":"101","author":"P Reddy","year":"2004","unstructured":"Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004;101(11):3921\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"1987_CR62","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/blood-2017-06-790469","volume":"130","author":"SW Choi","year":"2017","unstructured":"Choi SW, Braun T, Henig I, et al. Vorinostat plus tacrolimus\/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017;130(15):1760\u20137.","journal-title":"Blood"},{"issue":"4","key":"1987_CR63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1987_CR64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2174\/156800961506150805153230","volume":"15","author":"Y Li","year":"2015","unstructured":"Li Y, Chen K, Zhou Y, et al. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor. Curr Cancer Drug Targets. 2015;15(6):493\u2013503.","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01987-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01987-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01987-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:07:36Z","timestamp":1760368056000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01987-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1987"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01987-w","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Ethic Committee of Soochow Hopes Hematology Hospital. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from all participants. Maternal informed consent was obtained for minors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed informed consent. Copies of informed consent are available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"171"}}